When it comes to vaccinating the world, the simpler the dosing regimen the better. That’s why public-health officials welcomed Johnson & Johnson–Janssen Pharmaceuticals’ one-dose COVID-19 vaccine. The shot is 66% efficacious overall in protecting people from COVID-19 disease, and even more so in preventing the worst outcomes. After concerns were raised over rare blood-clotting side effects, U.S. health officials paused use of the shot in early April but resumed vaccination—with the potential clotting risk listed among the side effects—after determining the benefits outweigh the risks.
More Must-Reads from TIME
- Eyewitness Accounts From the Trump Rally Shooting
- From 2022: How the Threat of Political Violence Is Transforming America
- ‘We’re Living in a Nightmare:’ Inside the Health Crisis of a Texas Bitcoin Town
- Remembering Shannen Doherty, the Quintessential Gen X Girl
- How Often Do You Really Need to Wash Your Sheets?
- Why Mail Theft Is on the Rise
- Welcome to the Noah Lyles Olympics
- Get Our Paris Olympics Newsletter in Your Inbox